The Chemours Company

NYSE:CC 株式レポート

時価総額：US$3.5b

Chemours 将来の成長

Future 基準チェック /46

Chemours利益と収益がそれぞれ年間136%と5.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に68.7% 135.9%なると予測されています。

主要情報

136.0%

収益成長率

135.94%

EPS成長率

Chemicals 収益成長17.1%
収益成長率5.2%
将来の株主資本利益率68.73%
アナリストカバレッジ

Good

最終更新日11 May 2026

今後の成長に関する最新情報

分析記事 • May 08

The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

It's been a mediocre week for The Chemours Company ( NYSE:CC ) shareholders, with the stock dropping 17% to US$22.41 in...

Recent updates

分析記事 • May 08

The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

It's been a mediocre week for The Chemours Company ( NYSE:CC ) shareholders, with the stock dropping 17% to US$22.41 in...
Seeking Alpha • May 04

Chemours: Thesis Materialization In 2026 (Rating Downgrade)

Summary Chemours Company has delivered a 120%+ RoR in under six months, driven by strong refrigerant segment growth, especially Opteon adoption. Despite recent outperformance, CC now trades above my fair value target ($30/share), prompting a shift to a 'HOLD/Neutral' rating and portfolio rotation. CC remains fundamentally sound but faces persistent risks: high leverage ($3.5B net debt), regulatory liabilities, and cyclical end-market exposure, especially in TiO2. Future upside hinges on continued refrigerant growth, cost reductions, and deleveraging; current valuation reflects excessive optimism relative to near-term fundamentals. Read the full article on Seeking Alpha
ナラティブ更新 • Apr 22

CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside

Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).
ナラティブ更新 • Apr 08

CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside

Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).
ナラティブ更新 • Mar 24

CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership

Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).
ナラティブ更新 • Mar 09

CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook

Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.
ナラティブ更新 • Feb 22

CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside

Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.
ナラティブ更新 • Feb 08

CC: PFAS Class Action Risk Will Limit Future Shareholder Returns

Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.
分析記事 • Feb 03

The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth

The The Chemours Company ( NYSE:CC ) share price has done very well over the last month, posting an excellent gain of...
ナラティブ更新 • Jan 25

CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook

Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).
ナラティブ更新 • Jan 11

CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns

Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.
ナラティブ更新 • Dec 26

CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks

Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).
ナラティブ更新 • Dec 12

CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks

Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).
ナラティブ更新 • Nov 01

CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher

Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.
ナラティブ更新 • Oct 17

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).
ナラティブ更新 • Oct 03

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).
ナラティブ更新 • Sep 17

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.
分析記事 • Sep 03

The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

The Chemours Company ( NYSE:CC ) shares have continued their recent momentum with a 33% gain in the last month alone...
分析記事 • Jul 26

Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

The Chemours Company ( NYSE:CC ), is not the largest company out there, but it saw a significant share price rise of...
分析記事 • Jul 04

The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

The Chemours Company ( NYSE:CC ) shares have had a really impressive month, gaining 30% after a shaky period...
分析記事 • Jun 29

Chemours (NYSE:CC) Has No Shortage Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • May 14

We Like The Quality Of Chemours' (NYSE:CC) Earnings

Despite posting healthy earnings, The Chemours Company's ( NYSE:CC ) stock has been quite weak. Along with the solid...
分析記事 • Apr 25

Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

Key Insights The projected fair value for Chemours is US$23.71 based on 2 Stage Free Cash Flow to Equity Chemours is...
分析記事 • Mar 19

What Is The Chemours Company's (NYSE:CC) Share Price Doing?

The Chemours Company ( NYSE:CC ), might not be a large cap stock, but it saw significant share price movement during...
分析記事 • Mar 04

It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks

To the annoyance of some shareholders, The Chemours Company ( NYSE:CC ) shares are down a considerable 27% in the last...

業績と収益の成長予測

NYSE:CC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20286,712N/A3797247
12/31/20276,4014042625969
12/31/20266,0491821905179
3/31/20265,821-410154332N/A
12/31/20255,808-38651264N/A
9/30/20255,837-338-12265N/A
6/30/20255,850-430-54258N/A
3/31/20255,78810-797-455N/A
12/31/20245,78269-993-633N/A
9/30/20245,83563-675-289N/A
6/30/20245,814106-693-297N/A
3/31/20245,904-3299390N/A
12/31/20236,078-253186556N/A
9/30/20236,004-317-67235N/A
6/30/20236,294-87117405N/A
3/31/20236,566489337629N/A
12/31/20226,831578448755N/A
9/30/20227,031908485808N/A
6/30/20226,933881500818N/A
3/31/20226,673746460783N/A
12/31/20216,345608537814N/A
9/30/20216,108394712959N/A
6/30/20215,662256720947N/A
3/31/20215,100215581802N/A
12/31/20204,969219540807N/A
9/30/20204,984-117544854N/A
6/30/20205,140-117452843N/A
3/31/20205,455-46284738N/A
12/31/20195,526-52N/A650N/A
9/30/20195,637407N/A509N/A
6/30/20195,876606N/A563N/A
3/31/20196,284792N/A900N/A
12/31/20186,638995N/A1,140N/A
9/30/20186,7491,081N/A1,184N/A
6/30/20186,7051,013N/A954N/A
3/31/20186,476893N/A795N/A
12/31/20176,183746N/A640N/A
9/30/20175,930288N/A607N/A
6/30/20175,744285N/A693N/A
3/31/20175,540106N/A599N/A
12/31/20165,4007N/A594N/A
9/30/20165,438151N/A626N/A
6/30/20165,526-82N/A541N/A
3/31/20165,651-82N/A456N/A
12/31/20155,717-90N/A182N/A
9/30/20155,90675N/A372N/A
6/30/20156,052211N/A501N/A

アナリストによる今後の成長予測

収入対貯蓄率: CCは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。

収益対市場: CC今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: CC今後 3 年以内に収益を上げることが予想されます。

収益対市場: CCの収益 ( 5.2% ) US市場 ( 11.6% ) よりも低い成長が予測されています。

高い収益成長: CCの収益 ( 5.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CCの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 68.7 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/11 16:54
終値2026/05/08 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

The Chemours Company 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19

アナリスト機関
null nullAlembic Global Advisors
David ColemanArgus Research Company
Michael LeitheadBarclays